[Phase II study of epirubicin on breast cancer: a cooperative group study]. 1986

T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura

A phase II multicenter clinical study of epirubicin, a new anthracycline anticancer agent, was carried out in 46 patients with advanced breast cancer. The treatment schedule consisted of either 60 mg/m2 every three weeks or 40 to 50 mg/m2 on day 1 and day 8 every four weeks. Objective responses were observed in 23.7% of 38 evaluable patients (1 CR and 8 PR). Response rates according to previous chemotherapy were 50.0% (4/8) in previously non-treated patients and 36.4% (4/11) in patients previously treated with non-anthracyclines. The major adverse effect was bone-marrow suppression; leukopenia was observed in 82.1% of patients, anemia in 53.8% and thrombocytopenia in 20.0%. Other toxicities frequently observed were anorexia (55.0%), nausea-vomiting (55.0%) and alopecia (66.7%), but these seemed to be milder than those produced by doxorubicin.

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
July 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
August 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
January 1987, Anticancer research,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
June 1998, British journal of cancer,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
August 1991, Anti-cancer drugs,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
September 1986, Hinyokika kiyo. Acta urologica Japonica,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
July 2000, Breast cancer research and treatment,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
October 2002, Anti-cancer drugs,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
August 2000, Annals of oncology : official journal of the European Society for Medical Oncology,
T Tominaga, and M Kitamura, and Y Nomura, and O Abe, and K Enomoto, and T Ikeda, and M Izuo, and Y Iino, and T Taguchi, and K Tamura
July 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!